Pradeep Natarajan on Milvexian and Abelacimab vs Enoxaparin to Prevent VTE Post-Arthroplasty
Pradeep Natarajan, Director, Preventive Cardiology at Massachusetts General Hospital, shared on LinkedIn:
”Milvexian (oral FXIa inhibitor bid) and Abelacimab (FXI mAb x1) both have been shown to lower knee arthroplasty postop VTE vs enoxaparin (sc FXa and thrombin inhibitor).
In new RCT in same context, REGN7508Cat x1 was superior to enoxaparin sc daily but REGN9933A2 x1 was non-inferior.
Bleeding rates were similar but postop anemia less common for both vs enopaxarin.
– REGN7508Cat blocks the catalytic domain of FXI, so it blocks FXIa activity and FXI activation by FXIIa *and* thrombin.
This is generally similar to Abelacimab, which locks FXI in its inactive state.
– REGN9933A2 blocks the apple 2 domain of FXI, blocking FXIIa-mediated activation but permits thrombin-mediated activation.
So it’s primarily a contact pathway FXI inhibitor.
The effect estimate for reduced VTE with REGN7508Cat vs enoxaparin seems similar for Abelacimab at the higher doses in ANT-005 TKA.
Milvexian BID had lower VTE rates relative to enoxaparin only at the highest studied dose of AXIOMATIC-TKR with similar bleeding rates.
The data continue to show that the deepest inhibition of FXI (Abelacimab, now REGN7508Cat) is most favorable for postop VTE prevention after knee arthroplasty.
This study effectively demonstrates that FXI activation by both FXIIa *and* thrombin play a role in postop VTE.
In exploratory analyses, REGN7508Cat had lower VTE rates vs apixaban (oral FXa inhibitor), which is exciting to see.
Such a comparison was not performed in the Milvexian and Abelacimab postop VTE trials.”
Read the full article here.
Article: Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
Authors: Jeffrey I. Weitz, Aaron P. Kithcart, Meagan P. O’Brien, Oren Levy, Ethan Marin, Margaret Onisko, Kusha A. Mohammadi, Dateng Li, Karoline A. Meagher, Hannah H. Chang, Benjamin A. Olenchock, David E. Gutstein, Annelise Segers, Robin S. Roberts, Marc P. Bonaca, Gary E. Raskob
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC